AMOYTOP(SH:688278)2023-10-19 16:00Financial Performance - The company's revenue for Q3 2023 reached ¥556,211,279.57, representing a year-over-year increase of 29.86%[3] - Net profit attributable to shareholders for Q3 2023 was ¥166,727,548.24, a significant increase of 149.78% compared to the same period last year[3] - The basic earnings per share for Q3 2023 was ¥0.41, reflecting a growth of 156.25% year-over-year[4] - Total operating revenue for the first three quarters of 2023 reached ¥1,459,790,700.44, an increase of 28.6% compared to ¥1,143,196,090.93 in the same period of 2022[20] - Net profit for the first three quarters of 2023 was ¥368,906,357.86, compared to ¥200,405,087.53 in 2022, representing an increase of 83.9%[22] - Basic earnings per share for the first three quarters of 2023 were ¥0.91, up from ¥0.49 in the same period of 2022[22] - The company reported a profit before tax of ¥447,671,911.13 for the first three quarters of 2023, compared to ¥267,093,136.16 in 2022, representing a growth of 67.5%[21] Research and Development - Research and development expenses totaled ¥71,692,245.17 in Q3 2023, accounting for 12.89% of revenue, a decrease of 2.83 percentage points from the previous year[4] - Research and development expenses for the first three quarters of 2023 totaled ¥142,861,485.40, an increase from ¥101,007,835.52 in 2022, marking a rise of 41.4%[20] Assets and Liabilities - Total assets as of the end of Q3 2023 amounted to ¥2,137,295,279.48, marking a 20.85% increase from the end of the previous year[4] - Total liabilities as of the end of the third quarter of 2023 amounted to ¥447,436,990.17, up from ¥360,959,315.86 at the end of 2022, reflecting a growth of 23.9%[18] - Total equity attributable to shareholders reached ¥1,689,858,289.31, compared to ¥1,407,600,331.45 in 2022, an increase of 20.0%[18] - The company reported a deferred income tax asset of $45,868,219.71, down from $47,415,013.66, a decrease of $1,546,793.95[26] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥382,951,697.45, reflecting a growth of 68.87%[4] - The net cash flow from operating activities for the first three quarters of 2023 was CNY 382,951,697.45, an increase of 68.9% compared to CNY 226,767,086.97 in the same period of 2022[23] - Total cash inflow from operating activities reached CNY 1,530,035,737.29, up from CNY 1,185,427,484.98, reflecting a growth of 29.0% year-over-year[23] - Cash outflow from operating activities was CNY 1,147,084,039.84, compared to CNY 958,660,398.01 in the previous year, marking an increase of 19.7%[23] Shareholder Information - The company has a total of 7,055 common shareholders as of the end of the reporting period[7] - The largest shareholder, Yang Ying, holds 33.94% of the shares, totaling 138,077,266 shares[7] Donations and Community Engagement - The company's cash donations for the "China Chronic Hepatitis B Clinical Cure (Everest) Project" amounted to RMB 5.25 million in the first nine months of 2023, with total donations reaching RMB 45 million[13] - The company has completed cash donations of RMB 1.1 million for the "China Chronic Hepatitis B Nucleoside Treatment Study (Unnamed) Project" as of the reporting period[13] - The company has donated a total of 100,000 doses of Peginterferon to various foundations, with 13,700 doses donated in 2023[13] Operational Management - The company plans to continue its market expansion and product development initiatives, although specific figures were not disclosed in the report[14] - The company's short-term borrowings and other liabilities were not specified, indicating a focus on operational cash flow management[17] Accounting Changes - The company has implemented new accounting standards starting January 1, 2023, affecting the financial statements[25]